COVID-19 has considerably challenged health systems worldwide at a time when they’re also having to adapt to ageing populations, changes in patient needs and advances in technology.
Yet the pandemic has also helped expedite many changes that have the potential to reimagine healthcare. Taiwan is a case in point as it looks to build on its Covid response and accelerate health transformation.
Digital health is attracting attention in particular, leading to a growing number of alliances and partnerships between medical facilities and businesses involved in innovative areas such as AI, Big Data and IoT.
The government’s current initiative to develop Taiwan’s biomedical industry into an international hub for innovative biotech and medical R&D and a leader in precision health also offers business opportunities.
These developments are generating growing interest from international health and biomedical companies in Taiwan’s health industries market and the related potential for growth, investment and collaboration.
PwC has produced a comprehensive industry guide (up to date as of September 2022) to help interested parties to understand and explore Taiwan’s healthcare, biotechnology, pharmaceutical and medical device sectors.
To learn how PwC can be of help, contact our Health Industries Advisory Leader Lily Wong.